|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Aegerion Pharmaceuticals, Inc. (AEGR) announced that Japan's Ministry of Health, Labor & Welfare (MHLW) has approved the pricing authorization of its first product, Juxtapid.
Categories: Yahoo Finance Get free summary analysis Aegerion Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of Aegerion Pharmaceuticals, Inc. – BioMarin Pharmaceutical Inc. and Alnylam Pharmaceuticals, Inc (BMRN-US and ALNY-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 35.39 ... Read more (Read more...)
Aegerion (AEGR) reported a loss of 46 cents per share in the third quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 67 cents.